Arkolith/Insider Trading/AVTX/Form 4

Doyle Mittie

Chief Medical OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Apr 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$11K
Net Open-Market Flow
-$11K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)679$8.04$5K4K
Apr 1, 2026Sell(S)679$16.00$11K4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)679—$0148K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001918845-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML